Cambridge, MA – [Insert Date] – Ascletis Pharma Inc. has announced a significant advancement in its pursuit of novel obesity treatments, securing Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its investigational drug, ASC35. This pivotal approval paves the way for a Phase I clinical study of ASC35, a once-monthly subcutaneous (SQ) glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor (GLP-1R/GIPR) dual peptide agonist, designed to address the growing global obesity epidemic.
The upcoming Phase I trial will rigorously evaluate ASC35’s safety, tolerability, pharmacokinetics, and pharmacodynamics. This comprehensive assessment is crucial in understanding how the drug is absorbed, distributed, metabolized, and excreted by the body, as well as its biological effects. The study will involve a placebo-controlled, randomized, and double-blind design, a gold standard in clinical research ensuring unbiased evaluation. A total of 84 participants are slated to enroll, comprising individuals with obesity (defined by a Body Mass Index (BMI) of ≥30.0 kg/m²) and those who are overweight (BMI of ≥27.0 kg/m²) and present with weight-related comorbidities.
This FDA clearance marks a critical milestone for Ascletis Pharma, underscoring the potential of their innovative peptide pipeline. ASC35 represents a novel therapeutic candidate, distinguished by its dual-receptor agonism and a unique, patient-friendly delivery mechanism. The drug is independently discovered and developed, a testament to Ascletis’ proprietary AI-assisted structure-based drug discovery (AISBDD) platform. Furthermore, ASC35 will leverage the company’s ultra-long-acting platform (ULAP) technology to achieve its once-monthly subcutaneous administration, a key differentiator in a market increasingly seeking convenient and effective weight management solutions.
A New Era of Obesity Treatment: Understanding ASC35
ASC35 belongs to a class of drugs known as dual peptide agonists, targeting both GLP-1 and GIP receptors. These incretin hormones play a vital role in regulating glucose metabolism and appetite. By simultaneously activating both receptors, ASC35 aims to elicit a more potent and comprehensive effect on weight loss and metabolic health compared to single-receptor agonists. This dual-action mechanism is a significant area of research in the fight against obesity, with the potential to offer enhanced efficacy and address a broader spectrum of metabolic dysregulation.
The development of ASC35 is deeply rooted in Ascletis Pharma’s commitment to leveraging cutting-edge technology. The drug’s discovery and initial development were powered by the company’s AISBDD platform, which utilizes artificial intelligence to accelerate the identification and optimization of drug candidates. This AI-driven approach allows for a more efficient and targeted discovery process, potentially leading to novel therapeutics with improved profiles.
Crucially, ASC35’s innovative delivery system is a cornerstone of its therapeutic promise. The drug will be formulated using Ascletis’ proprietary Self-Assembling Lipid Depot (SALD) technology. This technology is designed to create an ultra-long-acting formulation that enables once-monthly subcutaneous injections. The SALD formulation is a low-viscosity solution containing lipids, organic solvents, and the active drug. Upon subcutaneous injection, it transforms into a gel-like depot within the body. This depot then gradually releases ASC35 over an extended period, typically one month or longer, thereby reducing the frequency of administration and potentially improving patient adherence and convenience. This innovative approach addresses a significant unmet need for patient-friendly treatment options in chronic disease management, particularly for conditions like obesity that require long-term therapeutic intervention.
The Clinical Trial Design: A Rigorous Evaluation of ASC35
The forthcoming Phase I study for ASC35 is meticulously structured to provide a comprehensive understanding of the drug’s profile. The trial is divided into two distinct parts:
Part A: Single Ascending Dose (SAD) Study
This initial phase will investigate the safety, tolerability, and pharmacokinetic profile of ASC35 at different single dose levels. Participants will receive a single subcutaneous injection of ASC35 at escalating doses. This part of the study is designed to identify the maximum tolerated dose (MTD) and to characterize how the drug is absorbed and eliminated from the body following a single administration. The SALD formulation’s unique properties will be closely monitored to ensure its stability and controlled release characteristics.
Part B: Multiple Ascending Dose (MAD) Comparison Study
This section of the trial introduces a critical head-to-head comparison. Part B will involve multiple ascending doses of ASC35, administered via its once-monthly SALD formulation. In parallel, participants will also receive the FDA-approved, once-weekly drug tirzepatide, a well-established GLP-1R/GIPR dual agonist currently used for weight management. This comparative arm is designed to directly assess ASC35’s performance against a leading therapy in the market. By comparing the safety, tolerability, and pharmacokinetic profiles of ASC35 with tirzepatide, researchers aim to understand ASC35’s potential advantages, particularly concerning its once-monthly dosing regimen and its formulation’s drug release characteristics. This comparison is vital for establishing ASC35’s potential place in the therapeutic landscape and highlighting its differentiated value proposition.
The trial’s design, encompassing both SAD and MAD studies with a direct comparison to tirzepatide, reflects a strategic approach to de-risking the drug’s development and generating robust data early on. The placebo-controlled, randomized, double-blind nature of the study ensures that the observed effects are attributable to ASC35 and not to external factors or participant/investigator bias.
Ascletis Pharma’s Vision: Addressing an Unmet Need in a Growing Market
The global obesity epidemic continues to escalate, posing significant health challenges and driving demand for effective, accessible, and sustainable treatment options. Ascletis Pharma’s leadership expresses strong optimism regarding ASC35’s potential to make a substantial impact.
Jinzi Jason Wu, Founder, Chairman, and CEO of Ascletis Pharma, highlighted the significance of the FDA’s IND clearance: "The FDA’s IND clearance for ASC35 once-monthly utilizing our proprietary SALD formulation is an exciting and significant milestone for Ascletis’ peptide pipeline to treat obesity as we advance multiple once-monthly to once-quarterly SQ administered peptides into the clinic." This statement underscores Ascletis’ broad commitment to developing long-acting injectable peptide therapies for obesity and related metabolic disorders. The company is strategically advancing a portfolio of such candidates, aiming to offer a range of dosing frequencies to meet diverse patient needs.
Wu further elaborated on the potential of ASC35: "ASC35’s potential for superior weight loss combined with a more versatile and patient-friendly once-monthly SQ injection will address a major unmet need in the rapidly growing obesity market." This vision positions ASC35 not just as another drug, but as a potentially transformative therapy that offers enhanced efficacy and a significantly improved patient experience. The "superior weight loss" claim, if substantiated in clinical trials, would be a powerful differentiator. Coupled with the convenience of a once-monthly injection, ASC35 could become a highly attractive option for patients and healthcare providers alike, particularly in a market that is experiencing rapid growth and innovation.
The obesity market is indeed expanding at an unprecedented rate, driven by increased awareness of its health consequences and the development of novel pharmacotherapies. Ascletis’ strategic focus on this area, combined with its innovative technological platforms, suggests a well-defined path towards addressing this critical public health issue.
A Broader Pipeline: Ascletis’ Commitment to Metabolic Health
The IND clearance for ASC35 is part of a larger, strategic initiative by Ascletis Pharma to develop a comprehensive pipeline of innovative treatments for metabolic diseases. The company has demonstrated a consistent commitment to advancing its drug candidates through clinical development.
In a related development, Ascletis Pharma recently announced the completion of subject enrollment in its 13-week U.S. Phase II study of ASC30 in April 2026. ASC30 is an oral small-molecule GLP-1 receptor agonist, specifically developed as a treatment for type 2 diabetes mellitus. This parallel development highlights Ascletis’ multifaceted approach to metabolic health, targeting both obesity and diabetes with different therapeutic modalities, including oral small molecules and injectable peptides. The successful completion of enrollment for ASC30’s Phase II study indicates progress in their broader R&D efforts and a commitment to addressing the interconnected nature of these conditions.
The successful development and commercialization of ASC35, alongside other pipeline candidates like ASC30, could position Ascletis Pharma as a significant player in the pharmaceutical landscape, particularly in the rapidly evolving fields of obesity and diabetes management. The company’s reliance on proprietary technologies like AISBDD and SALD/ULAP suggests a commitment to innovation and differentiation, which are key to navigating the competitive pharmaceutical industry.
Implications and Future Outlook
The FDA’s IND clearance for ASC35 represents a significant step forward for Ascletis Pharma and, more importantly, for individuals living with obesity. The drug’s novel dual-agonist mechanism, coupled with its once-monthly subcutaneous delivery via the SALD formulation, holds considerable promise for improving treatment outcomes and patient adherence.
The upcoming Phase I study will be crucial in validating these early-stage expectations. The results from the SAD and MAD studies, particularly the head-to-head comparison with tirzepatide, will provide critical insights into ASC35’s safety, efficacy, and tolerability relative to existing therapies. Positive data from this trial could pave the way for larger, more definitive Phase II and Phase III studies, bringing ASC35 closer to potential market approval.
The success of ASC35 could have several key implications:
- Enhanced Treatment Options: A safe and effective once-monthly obesity treatment would offer a valuable new option for patients who struggle with adherence to more frequent dosing regimens or who seek improved efficacy.
- Market Differentiation: The SALD formulation’s ultra-long-acting nature could provide a significant competitive advantage in a market that is already seeing innovation in drug delivery.
- Broader Therapeutic Impact: As a dual agonist, ASC35 has the potential to address not only weight loss but also improve other metabolic parameters, such as glucose control and lipid profiles, which are often compromised in individuals with obesity.
- Validation of Ascletis’ Platforms: The progression of ASC35 into clinical trials validates Ascletis’ proprietary AISBDD and SALD/ULAP technologies, potentially opening doors for further partnerships and the development of other long-acting peptide therapeutics.
As the clinical trial progresses, the scientific and medical communities will be closely watching ASC35’s development. Its journey through the regulatory process will be a key indicator of the future direction of obesity pharmacotherapy, emphasizing the growing importance of innovative drug design and patient-centric delivery systems in addressing one of the most pressing global health challenges of our time. Ascletis Pharma appears poised to make a substantial contribution to this critical area.
About the Author
